Printed From BioPortfolio.com
Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients
19:00 EST 19 Nov 2017 | AAAS
(European Society for Medical Oncology) Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.
Original Article: Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients
